ArticlePloS one2013
Prioritizing Potentially Druggable Mutations with dGene: An Annotation Tool for Cancer Genome Sequencing Data.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.International journal of cancer · 2022Article
- Systematic illumination of druggable genes in cancer genomes.Cell reports · 2022Article
- The druggable genome: Twenty years later.Frontiers in bioinformatics · 2022Article
- The PROTACtable genome.Nature reviews. Drug discovery · 2021Review
- Therapeutics-how to treat phase separation-associated diseases.Emerging topics in life sciences · 2020Review
- Integrated Computational Approaches and Tools forAllosteric Drug Discovery.International journal of molecular sciences · 2020Review
- Genetic-Driven Druggable Target Identification and Validation.Trends in genetics : TIG · 2018Review
- DGIdb 3.0: a redesign and expansion of the drug-gene interaction database.Nucleic acids research · 2018Article
- Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.Scientific reports · 2017Article
- Role of Structural Bioinformatics in Drug Discovery by Computational SNP Analysis: Analyzing Variation at the Protein Level.Global heart · 2017Review
- The druggable genome and support for target identification and validation in drug development.Science translational medicine · 2017Article
- Article
- DGIdb 2.0: mining clinically relevant drug-gene interactions.Nucleic acids research · 2016Article
- The impact of the Cancer Genome Atlas on lung cancer.Translational research : the journal of laboratory and clinical medicine · 2015Review
- New concepts in breast cancer genomics and genetics.Breast cancer research : BCR · 2014Review
- DGIdb: mining the druggable genome.Nature methods · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
A major goal of cancer genome sequencing is to identify mutations or other somatic alterations that can be targeted by selective and specific drugs. dGene is an annotation tool designed to rapidly identify genes belonging to one of ten druggable classes that are frequently targeted in cancer drug development. These classes were comprehensively populated by combining and manually curating data from multiple specialized and general databases. dGene was used by The Cancer Genome Atlas squamous cell lung cancer project, and here we further demonstrate its utility using recently released breast cancer genome sequencing data. dGene is designed to be usable by any cancer researcher without the need for support from a bioinformatics specialist. A full description of dGene and options for its implementation are provided here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.